Clinical study on safety and efficacy of fibroblast growth factor administration to nasal septal perforation

Otori Nobuyoshi0 个研究点目标入组 10 人开始时间: 2023年2月1日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Patients with serious hepatic, renal, or circulatory disorders
•2) Patients with malignant tumors
•3) Patients with a history of serious drug allergy or serious adverse drug reactions such as anaphylactic shock, those with a history of allergy to gelatin, and those allergic to anesthetics
•4) Patients who have participated in a clinical trial and taken an investigational drug within 4 weeks prior to obtaining consent
•5) Patients who are scheduled to undergo surgical treatment between the time consent is obtained and the end of the study period
•6) Patients who are pregnant or may become pregnant
•7) Patients who are breast-feeding
•8) Patients who have uncontrolled diabetes mellitus
•9) Patients with poorly controlled sinusitis or allergic rhinitis
•10) Patients at high risk of bleeding who are taking anticoagulants or antiplatelet agents
•11) Patients who are easily infected by autoimmune diseases, acquired immunodeficiency syndrome, taking immunosuppressive drugs
•12) Other subjects who are deemed inappropriate to participate in this research by the principal investigator (subinvestigator)

发起方

Otori Nobuyoshi